In the pursuit of optimal wellness, BONTAC presents a breakthrough cellular health product solution for cellular health with their Ginsenoside Rh2/Rg3 offerings. Harnessing the power of rare ginsenosides, they offer a transformative approach to supporting immune function, promoting albumin synthesis, inhibiting tumor cell growth, and facilitating tumor differentiation.
Understanding Ginsenosides
Ginsenosides, the primary active compounds found in traditional Chinese medicine ginseng, have long been revered for their therapeutic properties. BONTAC has been focusing on rare ginsenosides, specifically Ginsenoside Rh2/Rg3. These PPD-type rare ginsenosides exhibit enhanced biological activity, with Rh2 possessing one glucose group and Rg3 having two glucose groups attached to the C3 hydroxyl group of PPD.
Unveiling the Specifications
BONTAC adheres to product Ginsenoside Rh2/Rg3 with stringent specifications to ensure optimal quality and efficacy. Both Rh2 (CAS No.: 78214-33-2) and Rg3 (CAS. No.: 38243-03-7) present as yellow crystalline compounds. Their content is guaranteed to be at least 90%, reflecting BONTAC’s commitment to delivering potent and concentrated formulations. Additionally, the loss on drying is limited to 4.8%, ensuring the stability and integrity of the products.
Enhanced Immune Function
Ginsenoside Rh2 plays a pivotal role in bolstering the immune system. By incorporating this active ingredient, they enhance the patient’s immune function, providing relief from the pain experienced during treatment. This immune-regulating compound works to improve the body’s immune response, promoting overall well-being.
Promotion of Albumin Synthesis
Ginsenoside Rh2 acts as an immune regulator, stimulating the synthesis of albumin. This essential protein provides heat to the body, while also safeguarding and stabilizing immunoglobulins in the blood. By supporting albumin production, BONTAC’s products contribute to the maintenance of a healthy cellular environment.
Inhibition of Tumor Cell Growth
One remarkable attribute of Ginsenoside Rh2 is its ability to effectively reduce the toxicity associated with chemotherapy. By enhancing immunity, it alleviates post-chemotherapy discomfort. Moreover, this active ingredient demonstrates an inhibitory effect on the continuous growth of tumor cells, presenting a potential adjunctive therapy for cancer patients.
Conclusion
BONTAC’s Ginsenoside Rh2/Rg3 represents a cutting-edge solution for optimizing cellular health. With their remarkable ability to enhance immune function, promote albumin synthesis, inhibit tumor cell growth, and reverse abnormal tumor differentiation, these products offer a holistic approach to well-being.
